Lori S. Friedman

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

Georgia Hatzivassiliou, Kyung Song, Ivana Yen et al.|Nature|2010

Cited by 1.6kOpen Access

Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941

Teemu T. Junttila, Robert W. Akita, Kathryn L. Parsons et al.|Cancer Cell|2009

Cited by 830Open Access

Systematic generation of high-resolution deletion coverage of the Drosophila melanogaster genome

Annette L. Parks, Kevin R Cook, Marcia Belvin et al.|Nature Genetics|2004

Cited by 773Open Access

The Identification of 2-(1<i>H</i>-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-<i>d</i>]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer

Adrian Folkes, Khatereh Ahmadi, W. Alderton et al.|Journal of Medicinal Chemistry|2008

Cited by 746Open Access

Phosphatidylinositol-3-kinase (PI3K) is an important target in cancer due to the deregulation of the PI3K/ Akt signaling pathway in a wide variety of tumors. A series of thieno[3,2-d]pyrimidine derivatives were prepared and evaluated as inhibitors of PI3 kinase p110alpha. The synthesis, biological activity, and further profiling of these compounds are described. This work resulted in the discovery of 17, GDC-0941, which is a potent, selective, orally bioavailable inhibitor of PI3K and is currently being evaluated in human clinical trials for the treatment of cancer.

Involvement of Brca2 in DNA Repair

Ketan J. Patel, Veronica Yu, Hyun‐Sook Lee et al.|Molecular Cell|1998

Cited by 631Open Access

Is this you? Claim your profile.

Top publicationsby citations